BMRN Biomarin Pharmaceutical Inc

$58.58

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.

Website: https://www.biomarin.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1048477
Address
105 DIGITAL DRIVE, NOVATO, CA, US
Valuation
Market Cap
$11.35B
P/E Ratio
26.77
PEG Ratio
0.41
Price to Book
2.00
Performance
EPS
$2.21
Dividend Yield
—
Profit Margin
15.00%
ROE
8.05%
Technicals
50D MA
$67.06
200D MA
$71.90
52W High
$94.85
52W Low
$52.93
Fundamentals
Shares Outstanding
192M
Target Price
$96.87
Beta
0.30

BMRN EPS Estimates vs Actual

● Estimated
● Actual

BMRN News & Sentiment

Aug 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
BioMarin Pharmaceutical ( BMRN ) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aug 13, 2025 • Zacks Commentary BULLISH
Why BioMarin Pharmaceutical ( BMRN ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aug 12, 2025 • Benzinga SOMEWHAT-BULLISH
Is BioMarin Pharmaceutical Gaining or Losing Market Support? - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Pharmaceutical's BMRN short percent of float has fallen 15.79% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 2.72% of all regular shares that are available for trading.
Aug 12, 2025 • Zacks Commentary BULLISH
Why BioMarin Pharmaceutical ( BMRN ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aug 05, 2025 • Benzinga SOMEWHAT-BULLISH
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Q2 earnings rose 50% to $1.44 per share, topping estimates of $0.85. 2025 EPS guidance raised to $4.40-$4.55 vs. consensus of $3.45. The market's back, and these 3 income stocks are thriving. See them here→ On Tuesday, Biomarin Pharmaceutical Inc.
Aug 05, 2025 • Zacks Commentary NEUTRAL
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
Sentiment Snapshot

Average Sentiment Score:

0.140
50 articles with scored sentiment

Overall Sentiment:

Neutral

BMRN Reported Earnings

Apr 22, 2025
Mar 31, 2025 (Pre market)
0.48 Surprise
  • Reported EPS: $1.13
  • Estimate: $0.65
  • Whisper: —
  • Surprise %: 73.4%
Feb 20, 2025
Dec 31, 2024 (Pre market)
0.18 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.74
  • Whisper: —
  • Surprise %: 24.6%
Oct 29, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.52
  • Whisper: —
  • Surprise %: 5.8%
Aug 05, 2024
Jun 30, 2024 (Post market)
0.21 Surprise
  • Reported EPS: $0.56
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 60.0%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.11 Surprise
  • Reported EPS: $0.46
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 31.4%
Feb 22, 2024
Dec 31, 2023 (Post market)
-0.05 Surprise
  • Reported EPS: $0.18
  • Estimate: $0.23
  • Whisper: —
  • Surprise %: -21.7%
Nov 01, 2023
Sep 30, 2023 (Post market)
-0.02 Surprise
  • Reported EPS: $0.21
  • Estimate: $0.23
  • Whisper: —
  • Surprise %: -8.7%
Jul 31, 2023
Jun 30, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $0.29
  • Estimate: $0.23
  • Whisper: —
  • Surprise %: 26.1%
Apr 26, 2023
Mar 31, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $0.27
  • Estimate: $0.18
  • Whisper: —
  • Surprise %: 50.0%

Financials